PlumX Metrics
Embed PlumX Metrics

High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer

Frontiers in Oncology, ISSN: 2234-943X, Vol: 12, Page: 937934
2022
  • 2
    Citations
  • 0
    Usage
  • 10
    Captures
  • 1
    Mentions
  • 3
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    2
  • Captures
    10
  • Mentions
    1
    • News Mentions
      1
      • News
        1
  • Social Media
    3
    • Shares, Likes & Comments
      3
      • Facebook
        3

Most Recent News

Study Data from Department of Clinical Oncology Update Understanding of Prostate Cancer (High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized ...)

2022 NOV 03 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- New research on prostate cancer is the subject of

Article Description

Introduction: We hypothesized that increasing the pelvic integral dose (ID) and a higher dose per fraction correlate with worsening fatigue and functional outcomes in localized prostate cancer (PCa) patients treated with external beam radiotherapy (EBRT). Methods: The study design was a retrospective analysis of two prospective observational cohorts, REQUITE (development, n=543) and DUE-01 (validation, n=228). Data were available for comorbidities, medication, androgen deprivation therapy, previous surgeries, smoking, age, and body mass index. The ID was calculated as the product of the mean body dose and body volume. The weekly ID accounted for differences in fractionation. The worsening (end of radiotherapy versus baseline) of European Organisation for Research and Treatment of Cancer EORTC) Quality of Life Questionnaire (QLQ)-C30 scores in physical/role/social functioning and fatigue symptom scales were evaluated, and two outcome measures were defined as worsening in ≥2 (WS2) or ≥3 (WS3) scales, respectively. The weekly ID and clinical risk factors were tested in multivariable logistic regression analysis. Results: In REQUITE, WS2 was seen in 28% and WS3 in 16% of patients. The median weekly ID was 13.1 L·Gy/week [interquartile (IQ) range 10.2-19.3]. The weekly ID, diabetes, the use of intensity-modulated radiotherapy, and the dose per fraction were significantly associated with WS2 [AUC (area under the receiver operating characteristics curve) =0.59; 95% CI 0.55-0.63] and WS3 (AUC=0.60; 95% CI 0.55-0.64). The prevalence of WS2 (15.3%) and WS3 (6.1%) was lower in DUE-01, but the median weekly ID was higher (15.8 L·Gy/week; IQ range 13.2-19.3). The model for WS2 was validated with reduced discrimination (AUC=0.52 95% CI 0.47-0.61), The AUC for WS3 was 0.58, Conclusion: Increasing the weekly ID and the dose per fraction lead to the worsening of fatigue and functional outcomes in patients with localized PCa treated with EBRT.

Bibliographic Details

Nuradh Joseph; Alessandro Cicchetti; Riccardo Valdagni; Tiziana Rancati; Alan McWilliam; Adam Webb; Christopher J. Talbot; Paul R. Symonds; Kerstie Johnson; Tim Rattay; Petra Seibold; Jenny Chang-Claude; Claudio Fiorino; Cesare Cozzarini; Liv Veldeman; Renée Bultijnck; Valérie Fonteyne; Maarten Lambrecht; Karin Haustermans; Gert De Meerleer; Rebecca M. Elliott; Catharine M.L. West; Ananya Choudhury; REQUITE Consortium; Elena Sperk; Carsten Herskind; Marlon Veldwijk; Barbara Avuzzi; Tommaso Giandini; David Azria; Marie Pierre Farcy Jacquet; Marie Charissoux; Ana Vega; Miguel E. Aguado-Barrera; Antonio Gómez-Caamaño; Pierfrancesco Franco; Elisabetta Garibaldi; Giuseppe Girelli; Cinzia Iotti; Vittotorio Vavassori

Frontiers Media SA

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know